Применение мезенхимальных стволовых клеток способствует уменьшению степени ишемически-реперфузионного поражения различных органов в эксперименте: акцент на паракринные механизмы

Сегодня такие состояния, как острый инфаркт миокарда, ишемический инсульт, шоковое поражение органов являются ведущими причинами смерти в мире. Все данные состояния сопровождаются синдромом ишемически-реперфузионного повреждения - парадоксального процесса, при котором повреждение клеток ишемизированного органа продолжается после восстановления перфузии. Патогенез ишемически-реперфузионного повреждения весьма сложен и включает в себя сочетания таких процессов, как воспаление, метаболический дисбаланс, оксидативный стресс и т.д. Существующая сегодня терапия данных состояний является недостаточной, что дает основания искать альтернативные подходы в лечении ишемически-реперфузионного повреждения. Многие исследования демонстрируют эффективность использования мезенхимальных стволовых клеток как одного из методов терапии ишемически-реперфузионного повреждения. Особая роль в этом эффекте, по-видимому, принадлежит паракринным факторам. В данном обзоре мы рассматриваем множество работ по данной тематике и пытаемся обозначить основные патогенетические точки приложения мезенхимальных стволовых клеток при ишемически-реперфузионном повреждении.

ишемически-реперфузионное повреждение, мезенхимальные стволовые клетки, цитокины, воспаление, факторы роста, ischemia-reperfusion injury, mesenchymal stem cells, cytokines, inflammation, growth factors

1. Хубутия М.Ш., Темнов А.А., Вагабов А.В. и соавт. Низкомолекулярные пептидные препараты, полученные из культивированных стволовых клеток, при лечении острой почечной недостаточности // Трансплантология. 2011. №4. C. 20-25.

2. Angoulvant D, Ivanes F, Ferrera R, et al. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury // The Journal of Heart and Lung Transplantation. 2011. Vol. 30(1). P. 95-102.

3. Armiñán A, Gandia C, Garcia-Verdugo JM, et al. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction // J Am Coll Cardiol. 2010. Vol. 55. P. 2244-2253.

4. Arslan F, de Kleijn DP, Timmers L, et al. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets // Curr Pharm Des. 2008. Vol. 14. P. 205-1216.

5. Bi B, Schmitt R, Israilova M, et al. Stromal Cells Protect against Acute Tubular Injury via an Endocrine Effect // J Am Soc Nephrol. 2007. Vol. 18. P. 2486-2496.

6. Boyle AJ, McNiece IK, Hare JM. Mesenchymal stem cell therapy for cardiac repair // Methods Mol Biol. 2010. Vol. 660. P. 65-84.

7. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation Liver Transplantation // 2003. Vol. 9(7). P. 651-663.

8. Chang E.L., Lee S.H., Mun K.C, et al. Effect of artificial cells on hepatic function after ischemia-reperfusion injury in liver // Transplant. Proc. 2004. Vol. 36(7). P. 1959-1961.

9. Chen S, Chen L, Wu X, et al. Ischemia postconditioning and mesenchymal stem cells engraftment synergistically attenuate ischemia reperfusion-induced lung injury in rats // Journal of Surgical Research. 2012. Vol. 178(1). P. 81-91.

10. Davani, S., Marandin, A., Mersin, N., et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model // Circulation. 2003. Vol. 108. Suppl. 1. II253-II258.

11. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke // Journal of Clinical Neuroscience. 2009. Vol. 16. P. 12-20.

12. Eliopoulos N, Zhao J, Bouchentouf M, et al. Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection // AJP - Renal Physiol. 2010. Vol. 299(6). F1288-F1298.

13. Engler RL, Dahlgren MD, Peterson MA, et al. Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia // Am J Physiol. 1986. Vol. 251. H93-H100.

14. Feng Z, Ting J, Alfonso Z, et al. Fresh and cryopreserved, uncultured adipose tissue-derived stem and regenerative cells ameliorate ischemia-reperfusion-induced acute kidney injury // Nephrol Dial Transplant. 2010. Vol. 25. P. 3874 - 3884.

15. Gao X, Zhang H, Belmadani S et al. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury // Am J Physiol Heart Circ Physiol. 2008. Vol. 295. H2242-H2249.

16. Girn HR, Ahilathirunayagam S, Mavor AI et al. Reperfusion syndrome: cellular mechanisms of microvascular dysfunction and potential therapeutic strategies // Vasc Endovascular Surg. 2007. Vol. 41(4). P. 277-93.

17. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells // Nat Med. 2005. Vol. 11. P. 367-368.

18. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Aktmodified mesenchymal stem cell-mediated cardiac protection and functional improvement // The FASEB Journal. 2006. Vol. 20. P. 661-669.

19. Haider H, Ashraf M. Bone marrow stem cell transplantation for cardiac repair // Am J Physiol Heart Circ Physiol. 2005. Vol. 288. H2557-2567.

20. Jaeschke H. Mechanisms of reperfusion injury after warm ischemia of the liver // Journal of Hepatobiliary & Pancreatic Surgery. 1998. Vol. 5(4). P. 402-408.

21. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning // American Journal of Physiology, Gastrointestinal and Liver Physiology. 2003. Vol. 284(1). G15-G26.

22. Jiang H, Qu L, Li Y, et al. Bone Marrow Mesenchymal Stem Cells Reduce Intestinal Ischemia/Reperfusion Injuries in Rats // J Surg Res. 2009. Vol. 168(1). P. 127-134.

23. Junxi Wu, Jun Li, Nannan Zhang, et al. Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation // Basic Research in Cardiology. 2011. Vol. 106(3). P. 317-324.

24. Kanazawa H, Fujimoto Y, Teratani T, et al. Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate Hepatic Ischemia Reperfusion Injury in a Rat Model // PLoS One. 2011. Vol. 6(4). e19195.

25. Kudo M, Wang Y, Wani MA, et al. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart // J Mol Cell Cardiol. 2003. Vol. 35. P. 1113-1119.

26. Li Q, Yao D, Ma J, et al. Transplantation of MSCs in Combination with Netrin-1 Improves Neoangiogenesis in a Rat Model of Hind Limb Ischemia // Journal of Surgical Research. 2011. Vol. 166(1). P. 162-169.

27. Liu H, Liu S, Li Y, et al. The Role of SDF-1-CXCR4/CXCR7 Axis in the Therapeutic Effects of Hypoxia-Preconditioned Mesenchymal Stem Cells for Renal Ischemia/Reperfusion Injury // PLoS One. 2012. Vol. 7(4). e34608.

28. Manning E, Pham S, Li S, et al. Interleukin-10 delivery via mesenchymal stem cells: a novel gene therapy approach to prevent lung ischemia-reperfusion injury // Human Gene Therapy. 2010. Vol. 21(6). P. 713-727.

29. Matthew MJ. , Han X., Murthy SN., et al. Capturing the Stem Cell Paracrine Effect Using Heparin-Presenting Nanofibers to Treat Cardiovascular Diseases // J Tissue Eng Regen Med. 2010. Vol. 4 (8). P. 600-610.

30. Montzka K, Führmann T, Müller-Ehmsen J, et al. Grow factor and cytokine expression of human mesenchymal stromal cells is not altered in an vitro model of tissue damage // Cytotherapy. 2010. Vol. 12(7). 870-880.

31. Morigi M, Introna M, Imberti B, et al. Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice // STEM CELLS. 2008. Vol. 26(8). P. 2075-2082.

32. Morigi M., Rota C., Montemurro T., et al. Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury // STEM CELLS. 2010. Vol. 28(3). P. 513-522.

33. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium // Nature. 2001. Vol. 410 (6829). P. 701-705.

34. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival // Proc Natl Acad Sci U S A. 2001. Vol. 98(18). P. 10344-9.

35. Orlic D, Kajstura J, Chimenti S, et al. Transplanted adult bone marrow cells repair myocardial infarcts in mice // Ann N Y Acad Sci. 2001. Vol. 938. P. 221-229.

36. Park SS, Caballero S, Bauer G, et al. Long-Term Effects of Intravitreal Injection of GMP-Grade Bone-Marrow-Derived CD34+ Cells inNOD-SCID Mice with Acute Ischemia-Reperfusion Injury // IOVS. 2012. Vol. 53(2). P. 986-994.

37. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood. 2007. Vol. 109. P. 1422-1432.

38. Pittenger, MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics // Circ. Res. 2004. Vol. 95. P. 9-20.

39. Ploeg RJ, D’Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis // Transplantation. 1993. Vol. 55(4). P. 807-813.

40. Rolls A, Shechter R, London A, et al. Toll-like receptors modulate adult hippocampal neurogenesis // Nat Cell Biol. 2007. Vol. 9. P. 1081-1088.

41. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney // J Am Soc Nephrol. 2007. Vol. 18. P. 2439-2446.

42. Shake JG, Gruber PJ, Baumgartner WA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects // Ann Thorac Surg. 2002. Vol. 73(6). P. 1919-1925.

43. Sologub T.V., Romantsov M.G., Kremen N.V, et al. Free radical processes and inflammation (pathogenic, clinical and therapeutic aspects). Manual for physicians. Moscow: Akademiya Estestvoznaniya, 2008. ISBN 978-5-98654-030-6.

44. Sun CK, Yen CH, Lin YC, et al. Autologous Transplantation of Adipose-Derived Mesenchymal Stem Cells Markedly Reduced Acute Ischemia-Reperfusion Lung Injury in a Rodent Model // Journal of Translational Medicine. 2011. Vol. 9. P. 118.

45. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection // Journal of Gastroenterology and Hepatology. 2003. Vol. (8). P. 891-902.

46. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms // Am J Physiol Renal Physiol. 2005. Vol. 289. F31-42.

47. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart // Circulation. 2002. Vol. 105(1). P. 93-98.

48. Tomita S, Mickle DA, Weisel RD, et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation // J. Thorac. Cardiovasc. Surg. 2002. Vol. 123. P. 1132-1140.

49. Wang JS, Shum-Tim D, Chedrawy E, et al. The coronary delivery of marrow stromal cells for myocardial regeneration: pathophysiologic and therapeutic implications // J. Thorac. Cardiovasc. Surg. 2001. Vol. 122. P. 699-705.

50. Wang Y, Abarbanell AM, Herrmann JL, et al. TLR4 Inhibits Mesenchymal Stem Cell (MSC) STAT3Activation and Thereby Exerts Deleterious Effects on MSC-Mediated Cardioprotection // PLoS One. 2010. Vol. 5(12). e14206.

51. Webber MJ, Han X, Murthy SN, et al. Capturing the Stem Cell Paracrine Effect Using Heparin-Presenting Nanofibers to Treat Cardiovascular Diseases // J Tissue Eng Regen Med. 2010. Vol. 4(8). P. 600-610.

52. Yagi H, Soto-Gutierrez A, Kitagawa Y, et al. Bone Marrow Mesenchymal Stromal Cells Attenuate Organ Injury Induced by LPS and Burn // Cell Transplant. 2010. Vol. 19(6). P. 823 - 830.

53. Yen-Ta Chen, Cheuk-Kwan Sun, Yu-Chun Lin, et al. Adipose-Derived Mesenchymal Stem Cell Protects Kidneys against Ischemia-Reperfusion Injury through Suppressing Oxidative Stress and Inflammatory Reaction // Journal of Translational Medicine. 2011. Vol. 9.P. 51.

54. Zhang C, Wu J, Xu X, et al. Direct relationship between levels of TNF-alpha expression and endothelial dysfunction in reperfusion injury // Basic Res Cardiol. 2010. Vol. 105. P. 453-464.